$599

Sanofi Q3 ’23 Earnings; Additional Sernova Cell Pouch Data; GSK Initiates New Ph2a NASH Study

Three cardiometabolic-related news items have been observed: Sanofi hosted its Q3 ’23 earnings call (press release; slides; infographic); Sernova announced positive interim results from its ongoing Ph1/2 Cell Pouch study (view press release); and GSK initiated a new Ph2 study evaluating GSK4532990 in participants with NASH and suspected NASH (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.